Clinical effects of Cinobufosin Injection combined with RALOX-HAIC regimen on patients with hepatocellular carcinoma
10.3969/j.issn.1001-1528.2025.03.015
- VernacularTitle:华蟾素注射液联合RALOX-HAIC方案对肝细胞癌患者的临床疗效
- Author:
Ming-yuan WU
1
;
Yun-ke YANG
;
Xin-tong GAO
;
Zhao-shuo YANG
;
Zhen-feng ZHU
Author Information
1. 复旦大学附属中山医院中西医结合科,上海 200000
- Publication Type:Journal Article
- Keywords:
Cinobufosin Injection;
RALOX-HAIC regimen;
hepatocellular carcinoma;
toxic and side effects;
inflammatory responses
- From:
Chinese Traditional Patent Medicine
2025;47(3):802-806
- CountryChina
- Language:Chinese
-
Abstract:
AIM To investigate the clinical effects of Cinobufosin Injection combined with RALOX-HAIC regimen on patients with hepatocellular carcinoma.METHODS Ninety-two patients were randomly assigned into control group(46 cases)for intervention of RALOX-HAIC regimen,and observation group(46 cases)for intervention of both Cinobufosin Injection and RALOX-HAIC regimen.The changes in short-term effects,survival situation,inflammatory indices(LCN2,NLRP3 inflammasome,NLR,PLR),immune indices(NK cells,CD8+T cells,IL-17,Th17/Treg)and incidence of toxic and side effects were detected.RESULTS Based on mRECIST,the observation group demonstrated higher disease control rate and objective remission rate than the control group(P＜0.05),along with lower disease progression(P＜0.05).After the treatment,the two groups displayed decreased inflammatory indices,IL-17,Th17/Treg(P＜0.05),and increased NK cells,CD8+T cells(P＜0.05),especially for the observation group(P＜0.05).The observation group exhibited lower incidence of abdominal pain,nausea,vomiting,diarrhea,leukopenia and thrombocytopenia than the control group(P＜0.05),and no significant differences in overall survival and incidence of other toxic and side effects were found between the two groups(P＞0.05).CONCLUSION For the patients with hepatocellular carcinoma,Cinobufosin Injection combined with RALOX-HAIC regimen can safely and effectively enhance body immune functions,and reduce in vivo immune indices.
